{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:19:23Z","timestamp":1753877963221,"version":"3.41.2"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Sucralfate is a commonly prescribed medication in use for decades. Despite the availability of more effective medications for acid\u2010dyspeptic conditions, including proton pump inhibitors and histamine H2\u2010receptor antagonists, sucralfate continues to be utilized for upper gastrointestinal symptoms. We reviewed the limited evidence base supporting the approval and ongoing usage of sucralfate and performed a cost analysis using the <jats:italic>ClinCalc<\/jats:italic> database. The financial impact of sucralfate was comparable to famotidine, lansoprazole and ranitidine. We encourage further studies to accurately gauge the true clinical efficacy of sucralfate and to question its ongoing prescription until then.<\/jats:p>","DOI":"10.1111\/bcpt.70070","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:53:05Z","timestamp":1749880385000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?"],"prefix":"10.1111","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-304X","authenticated-orcid":false,"given":"Neha","family":"Wadhavkar","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Brown University  Providence Rhode Island USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Varnum","sequence":"additional","affiliation":[{"name":"UMass Memorial Specialty Pharmacy UMass Memorial Medical Center  Worcester Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven\u00a0F.","family":"Moss","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Brown University  Providence Rhode Island USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u201097\u20102\u2010269"},{"key":"e_1_2_10_3_1","unstructured":"P.KudaravalliandS.John. \u201cSucralfate. [Updated 2022 Feb 25]. In: StatPearls [Internet] \u201d Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2010. Available From:https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551527\/."},{"key":"e_1_2_10_4_1","unstructured":"Department of Health and Human Services.2017.Carafate\u00ae (Sucralfate) Oral Suspension\u2014accessdata.fda.gov. The United States Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019183s019lbl.pdf."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198427030-00002"},{"issue":"4","key":"e_1_2_10_6_1","first-page":"307","article-title":"Sucralfate\u2014Alternative Therapy for Peptic\u2010Ulcer Disease","volume":"1","author":"Garnett W. R.","year":"1982","journal-title":"Clinical Pharmacy"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90830-8"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909093113"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001538"},{"key":"e_1_2_10_10_1","unstructured":"P.SeanandP.Kane.2022.The Top 200 Drugs of 2021. ClinCalc https:\/\/clincalc.com\/DrugStats\/Top200Drugs.aspx."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13944"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618809927"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:53:05Z","timestamp":1750920785000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.70070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/bcpt.70070"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.70070","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"type":"print","value":"1742-7835"},{"type":"electronic","value":"1742-7843"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"2025-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70070"}}